Education
Postgraduate Training
Specialty Boards
Academic and Professional Appointments
Honors and Awards
Society Memberships
Grant Support
Publications
Papers Submitted or In Preparation
Chapters in Preparation or In Press
Abstracts and Presentations
Invited Presentations
EDUCATION:
1994, Medical College of Ohio, Toledo, OH, MSBS Urological Sciences
1988, Vanderbilt -Nashville, TN, MD Medicine
1984, Vanderbilt -Nashville, TN, BS Chemistry
Top of page
POSTGRADUATE TRAINING:
7/95-6/00: Fellowship in Urologic Oncology
M.D. Anderson Cancer Center, Houston, TX
7/94-6/95: Fellowship in Organ Transplantation
University of Texas Medical School, Houston, TX
7/89-6/94: Resident in Urology
Medical College of Ohio, Toledo, OH
7/88-6/89: Intern in General Surgery
Loyola University Medical Center, Maywood, IL
Top of page
SPECIALTY BOARDS:
Board Certified, American Board of Urology - 02/02
Top of page
ACADEMIC AND PROFESSIONAL APPOINTMENTS:
9/00-present: Assistant Professor
University of Minnesota
7/95-6/96, 7/98-present: Junior Faculty Associate
M.D. Anderson Cancer Center
7/94-6/95: Specialist in Organ Transplantation
Univ. of TX Medical School, Houston
Top of page
HONORS AND AWARDS:
2/98, 3rd prize, 1998 Ambrose/Reed Socioeconomic Prize Essay Contest, AUA 1998
3/93, 1st prize, Toledo Surgical Society Residents' Essay Contest
3/93, 1st place (laboratory section), Ohio Urological Society Residents' Essay Contest
3/91, Honorable Mention, Ohio Urological Society Residents' Essay Contest
5/83, Phi Beta Kappa
Top of page
SOCIETY MEMBERSHIPS:
American Urological Association
Society of Transplantation and Vascular Surgery
American Society of Transplant Physicians
American Association of Cancer Research
Top of page
GRANT SUPPORT:
7/98-6/99: Clinical Fellows Research Award - MD Anderson Cancer Center
7/97-6/98: Clinical Fellows Research Award - MD Anderson Cancer Center
7/97-6/98: American Cancer Society Clinical Fellowship Award
7/96-6/97: Clinical Fellows Research Award - MD Anderson Cancer Center
7/95-6/96: Clinical Fellows Research Award - MD Anderson Cancer Center
7/92-6/93: Douglas Foundation - Toledo, OH
Top of page
PUBLICATIONS:
1. Bosch, F., Bouscarel, B., Slaton, J., Blakemore, P.F., and Exton, J.H., Epidermal growth factor mimics the effects of insulin in rat hepatocytes. Biochem J. 239: 523-530, 1986.
2. Morris, J.A., Slaton, J., and Gibbs, D., Vascular organ procurement in the trauma population. J. Trauma, 29(6): 782, 1989.
3. Slaton, J. W., Howard, J., and Selman, S.H., The successful treatment of necrotizing pancreatitis in a renal transplant recipient. HPB Surgery, 7: 157, 1993.
4. Slaton, J. W., Kropp, K.A., Jhunjhunwala, J.S., and Selman, S. H., Cyclosporine versus azathioprine: A five year follow-up of 200 consecutive renal transplant recipients. J Urol. 152:582, 1994.
5. Slaton, J.W. and Kropp, K.A., Conservative management of suspected bladder perforation after augmentation enterocystoplasty. J Urol., 152:713, 1994.
6. Slaton, J.W., Hampton, J.A., Selman, S.H., Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J Urol, 152:1594, 1994.
7. Slaton, J.W., Kropp, K.A., Merrick, H.W., Dobelbower, R.R., and Selman, S.H., The use of ileal urinary conduits in conjunction with intraoperative radiotherapy. J Surg Onc 58:222-224,1995.
8. Slaton, J.W., The current status of rescue therapy for refractory allograft rejection. Transpl and Immuno Let. 11(3):3-14, 1995.
9. Kahan B.D., Murgia M.G., Slaton, J., and Napoli K., Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther. Drug Monit. 17(6): 672-5, 1995.
10. Slaton, J.W. and Kahan, B.D., Case report: sirolimus rescue therapy for refractory renal allograft rejection. Transplantation 61(6): 977-979, 1996.
11. Slaton, J.W. and Kropp, K.A., Proximal ureteral stent migration: an avoidable complication? J. Urol. 155(1): 58-61, 1996.
12. Kerman, R.H., Susskind, B., Slaton, J., Lewis, R.M., Heydari, A., Ruth, J., Williams, J., Van Buren, C.T., Katz, S.M., and Kahan, B.D., Improved graft survival in 100 retransplant recipients following AHG-negative crossmatching. Transplant Proc. 29:1451-3, 1997.
13. Slaton, J.W., Dinney, C.P.N., Veltri, R. W., Miller, M. C., Liebert M., O'Dowd, G. J., and Grossman, H. B., DNA ploidy enhances the cytologic prediction of recurrent transitional cell carcinoma of the bladder. J. Urol. 158: 806-811, 1997.
14. Slaton, J.W., Balbay, M.D., Levy, D.A., Pisters, L.L., Nesbitt, J.C., Swanson, D.A and Dinney, C.P.N., Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology 50:673-677,1997.
15. Kaufman, A.M., Slaton, J.W., Czerniak, B.A. and Grossman, H.G., Transitional cell carcinoma of the bladder with involvement of vasa deferentia. J. Urol. 159:204-205, 1997.
16. Levy, D.A., Swanson, D.A., Slaton, J.W., Ellerhorst, J., and Dinney, C.P.N., Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J. Urol. 159: 1168-1173, 1998.
17. Levy, D.A., Slaton, J.W., Swanson, D.A., and Dinney, C.P.N. A stage-based protocol for tumor surveillance after nephrectomy for renal cell carcinoma. J. Urol. 159: 1163-1167, 1998.
18. Slaton, J.W., Levy D.A., Swanson D. A., Morris, M., Grossman, H.G., and Dinney, C.P.N., A stage-specific approach to tumor surveillance after radical cystectomy for transitonal cell carcinoma of the bladder. J Urol 162:710-4, 1999.
19. Donat S.M., Slaton J.W., Pisters, L.L., Swanson, D.A. Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion. J Urol 162:1599-160, 1999.
20. Slaton, J.W., Perrotte, P., Inoue, K., Dinney, C.P.N., and Fidler, I.J., Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of doe and schedule. Clin Cancer Res 5:2726-34, 1999.
21. Balbay, M.D., Slaton, J. W., Trane, N.,Skibber, J., and Dinney, C. P. N., Rationale for bladder-sparing in patients with locally advanced rectal carcinoma. Cancer 86:2212-16, 1999.
22. Pettaway, C.A., Pisters, L.L., Finn, D., Slaton, J. W., and Logothetis, C.J., Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050, 2000.
23. Inoue, K., Slaton, J. W., Perrotte, P., Kim, S. J., Eve, B. E, Bar-Eli, M. , Radinsky, R. and Dinney, C.P.N. Interleukin-8 expression regulates tumorigenicity in human bladder cancer Cancer Res 60:2290-9, 2000.
24. Inoue, K., Slaton, J.W., Eve, B.Y, Paul Perrotte, P., Balbay, M. D., Yano, S. Bar-Eli, M., Radinsky, R., Pettaway, C.A., and Dinney, C.P.N. Interleukin-8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2104-19, 2000
25. Perrotte, P., Wood, M., Slaton, J.W., Wilson, DR., Pagliaro, L., Price, R.E., and Dinney, C.P.N. Biosafety of in vivo adenovirus-p53 (Ad-p53) intravesical administration in mice. Urology 2000 Jul;56(1):155-9
26. Inoue, K., Slaton, J.W., Davis, D.W., Hicklin, D.J., McConkey, D., Radinsky, R. and Dinney, C.P.N., Therapy of metastatic transitional cell carcinoma of the bladder with the anti-vascular endothelial cell growth factor receptor (flk1/KDR) monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6:2635-43, 2000.
27. Izawa, J.I., Slaton, J.W., Kedar, D., Karashima, T., Perrotte, P., Czerniak, B., Grossman, H.B., Dinney, C.P. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 8::9-15, 2000.
28. Inoue, K., Perrotte, P, Wood, C.G., Slaton, J.W., Sweeney, P., Dinney, C.P. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res. 6:4422-31, 2000.
29. Inoue, K., Slaton, J.W., Perrotte, P., Davis, D.W., Bruns, C. J., Hicklin, D.J., McConkey, D., Radinsky, R. and Dinney, C.P.N Paclitaxel enhances the effects of the anti-epidermal growth factor receptor Imclone C225 in mice with metastatic human bladder transitional cell carcinoma Clin Cancer Res. 6:4874-84, 2000.
30. Inoue K, Slaton J.W., Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000 Dec;6 (12):4866-73.
31. Slaton, J.W., Inoue, K, Perrotte, P., El-Naggar, A.K. Swanson, D.A., Fidler, I.J., and Dinney, C.P.N. Expression level of metastasis-angiogenesis regulating genes correlates with advanced pathological stage of renal cell carcinoma. In press in The American Journal of Pathology.
32. Slaton, J.W., Morganstern, N., Levy, D.A., Ayala, A., Santos, M.W., and Pettaway, C.A., Vascular invasion and tumor stage are independent prognosticators of lymph node metastasis in squamous penile cancer. J Urol 165:1138-42,2001.
33. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep. 8:955-64, 2001.
34. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res.7:2840, 2001.
35. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 167:65-70, 2002
36. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol. 2002 Apr;167(4):1638-42.
37. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002 Apr;8(4):1258-70, 2002.
38. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 8:1253-64, 2002.
39. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, shuin T. The prognostic value of value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Rels. 8:1863-70, 2002.
40. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003 Jun;61(6):1151-5.
41. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15;21(12):2247-53.
42. Wilson MJ, Haller R, Slaton JW, Wasserman NF, Sinha AA . Dipeptidylpeptidase IV activities in prostatic secretions. Adv Exp Med Biol. 2003;524:257-60.
43. Monga M, Dretler SP, Landman J, Slaton JW, Conradie MC, Clayman RV. Maximizing ureteroscope deflection: "play it straight".Urology. 2002 Nov;60(5):902-5.
44. Wilson MJ, Haller R, Slaton JW, Wasserman NF, Sinha AA. Dipeptidylpeptidase IV activities in prostatic secretions. Adv Exp Med Biol. 2003;524:257-60.
45. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003 Jun;61(6):1151-5.
46. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003 Sep-Oct;21(5):327-33.
47. Unger GM, Davis AT, Slaton JW, Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets. 2004 Feb;4(1):77-84.
48. Naya Y*, Slaton JW*, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol. 2004 Mar;171(3):1093-7. * Equal contributors.
49. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology. 2004 Jan;63(1):46-50.
50. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb;171(2 Pt 1):570-4.
51. Hoffman N, Lukasewycz SJ, Canales B, Botnaru A, Slaton JW, Monga M. Percutaneous renal stone extraction: in vitro study of retrieval devices. J Urol. 2004 Aug;172(2):559-61.
52. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res. 2004 Dec;2(12):712-21.
Top of page
PAPERS SUBMITTED OR IN PREPARATION:
1. Slaton, J. W., Nelkin. G., and Killion, J. J., Therapy of lung metastases of murine renal adenocarcinoma with macrophage activator, CGP 31362, and IL-2 encapsulated into multilamellar liposomes. Submitted to Cancer Immunotherapy and Therapeutics.
2. Slaton, J.W. Perrotte, P, Inoue, K, Beilenberg, D, Eve, B, and Dinney, CPN, Interferon alpha restores the balance between the expression of MMP-9 and E-cadherin in human transitional cell carcinoma. Submitted to Cancer Research
3. Inoue, K., Wood, C.G., Slaton, J.W. and Colin P.N. Dinney. Interleukin-8 is a target for gene therapy in transitional cell carcinoma of the bladder. Submitted to Human Gene Therapy.
4. Slaton, J.W., Wood, C.G., Inoue, T. Karashima,, T., Davis, D.W., McConkey, D. and Dinney, C.P.N., Adenoviral-mediated gene therapy with antisense interleukin-8 for human prostate cancer.
5. Slaton, J.W., Inoue, K., Karashima, T., Tamashita, M.,, Pagliaro,, L., Benedict, W.F., and Dinney, C.P.N., Adenoviral p53 gene therapy enhances the efficacy of cytotoxic chemotherapy of transitional cell carcinoma of the bladder.
Top of page
CHAPTERS IN PREPARATION OR IN PRESS:
1. Slaton, J.W. and Swanson, D.A., Radical Nephrectomy. In Comprehensive Textbook of Urologic Oncology. Eds Vogelzang, N. et al, 2000
2. Perrotte, P., Slaton, J.W., and Dinney, C.P.N. Surgical Management of Bladder Cancer. In Surgical Oncology. Ed. Golematis, B. Ch.
3. Slaton, J.W. and Swanson, D.A., Renal Cell Carcinoma: Diagnosis and Staging. In Current Clinical Oncology: Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management. Ed. R. M. Bukowski and A. C. Novick,, Humana Press Inc., Totowa, NJ, 2000.
4. Slaton, J.W., Swanson, D.A., Surgery for Metastatic Disease. In Renal and Adrenal Tumors - Biology and Management; eds Belldegrun, A, Figlin, RA, Vaughan E.D., Ritchie, A., and Oliver, T. (Oxford University Press). 2000.
5. Slaton, J.W., Benedict, W.F., and Dinney, C.P.N. p53: Mechanism of action, prognostic value, and target for therapy. In press in Urology.
Top of page
ABSTRACTS/PRESENTATIONS:
1. Morris, J.A., Slaton, J.W., and Gibbs, D., Vascular organ procurement in the trauma population. Presented on the podium to the Eastern Association of Trauma Surgeons, 1/89
2. Slaton, J.W., Kropp, K.A., Jhunjhunwala, J.S., Wolfe, C., and Selman, S.H., Cyclosporine versus azathioprine: A five-year follow-up of 200 consecutive renal transplant recipients. Presented on the podium to the Ohio Urologic Society in 3/91 (honorable mention) and as a poster at the North Central Section of the American Urological Society in Phoenix, AZ in 11/91.
3. Slaton, J.W., Kropp, K.A., Merrick, H.W., and Selman, S.H., The use of ileal urinary conduits in conjunction with intraoperative radiotherapy. Presented on the podium at the North Central Section of the AUA in Phoenix, AZ in 11/91.
4. Slaton, J.W., Kropp, B P., Jhunjhunwala, J. S., Selman, S.H., Wolfe, C., and Kropp, K.A., Steroid complications in 200 consecutive renal transplant recipients: Relationship to methylprednisolone pulse therapy. Presented on the podium to the Ohio Urological Society in 3/92.
5. Slaton, J.W., Hampton, J.A., and Selman, S.H., Inhibition of in vitro invasion of transitional cell carcinoma by exposure to alkyllysophospholipids. Presented on the podium to the Toledo Surgical Society 2/93 and Ohio Urological Society in 3/93; and as a poster at the 89th Annual American Urological Association in San Francisco, 5/94.
6. Slaton, J.W., and Kropp, K.A., Conservative management of suspected bladder perforations after augmentation enterocystoplasty. Presented on the podium to the North Central Section of the AUA , Millwaukee, WI, 10/93 and the Urology Section of the Academy of Pediatrics, Washington, DC, 11/93
7. Slaton, J.W., and Kropp, K. A., Ureteral stent migration: an avoidable complication? Presented on the podium to the Ohio Urological Society in 3/94 and North Central Section - AUA, 10/94.
8. Slaton, J.W., Murgia, M.G., Jordan, S., and Kahan, B.D., Rapamycin in conjunction with cyclosporine and steroids in HLA-DR mismatched living-related renal transplants. Presented on the podium at the 90th annual AUA in Las Vegas, 4/95. and at the Ortho Transplant Fellow Workshop in New Orleans, LA, 5/95.
9. Slaton, J.W., Browne, B.J., Lamki, L.M., Verani, R., Kahan, B.D., Tc-99m MAG3 renal scan predicts the presence of acute rejection but not the pathologic grade. Presented as a poster at the American Society of Transplant Physicians, Chicago, 5/95.
10.Slaton, J.W., Browne, B.J., Lamki, L.M., Kahan, B.D., Tc-99m MAG3 clearance predicts delayed graft function in renal transplants. Presented as a poster at the American Society of Transplant Physicians, Chicago, 5/95.
11. Lamki, L.M. Slaton, J.W., Browne, B.J., Barron, B., Kahan, B.D. Tc-99m MAG3 Clearance within 3 hours of renal transplatation is a good predictor of delayed graft function and risk of cyclosporine toxicity. Presented at annual meeting of the Radiological Society of North America 11/27/95 in Chicago, IL.
12. Lamki, L.M., Slaton, J.W., Browne, B.J., Barron, B., Kahan, B.D. Nuclear evaluation of renal allograft: prediction of delayed graft function by Tc-99m-MAG3 and of acute rejection by Tc-99m DTPA. Presented at theannual meeting of the Southwestern Chapter of the Society of Nuclear Medicine 3/30/96, Austin, TX.
13. Lamki, L.M., Slaton, J.W., Browne, B.J., Barron, B., Kahan, B.D. Tc-99m-MAG3 clearance at 3 hrs is a good predictor of delayed renal graft function (DGF) while Tc-99m-DTPA perfusion score during follow-up, can predict rejection. Presented at Society of Nuclear Medicine, 6/96, Denver, CO.
14. Slaton, J.W., Dinney, C.P.N., Liebert, M., Grossman, B., Miller, C., O'Dowd, G., Veltri, R. DNA ploidy enhances cytologic prediction of recurrences of transitional cell carcinoma of the bladder. Presented as a poster at the 91st AUA May, 1996 in Orlando, FL.
15. Levy, D.A., Slaton, J.W., Ellerhorst, J., Swanson, D. A., and Dinney, C. P. N., Feasibility of cytoreductive surgery prior to systemic biologic therapy in carefully selected metastatic renal cell carcinoma. Presented as a poster at the 92nd Annual AUA in New Orleans, 4/97.
16. Levy, D.A., Slaton, J.W., Swanson, D.A., and Dinney, C.P.N. A stage-based protocol for surveillance in patients with local renal cell carcinoma (RCC). Presented as a poster at the 92nd Annual AUA in New Orleans, 4/97.
17. Donat, S.M. and Slaton, J.W. Early nasogastric removal in conjunction with reglan after radical cystectomy and urinary diversion. Presented on the podum at the 92nd Annual AUA in New Orleans, 4/97.
18. Veltri, R.W., Miller, M.C., Slaton, J.W., Dinney, C.P.N., Liebert, M., Grossman, H.B., and O'Dowd, G.J. Computer-assisted quantitative nuclear grading (QNG) can predict bladder cancer recurrence using bladder cancer cytology samples. Presented as a poster at the 92nd Annual AUA in New Orleans, 4/97.
19. Slaton, J.W., Dinney, C.P.N., and Grossman, H.B. A stage-based protocol for tumor surveillance after radical cystectomy. Presented as a poster at the 92nd Annual AUA in New Orleans, 4/97.
20. Slaton, J.W., Levy, D.A., Dinney, C.P.N., Swanson, D.A., and Grossman, H. B. Stage-driven surveillance protocols for recurrence of renal and bladder cancer after definitive local surgery. Presented as a poster to the 1st Annual MDACC Trainees Competition, Houston, TX, May, 1997.
21. Slaton, J.W., Balbay, M.D., Levy, D.A., Nesbitt, J.C., Swanson, D.A., Pisters, L.L., and Dinney, C.P.N., Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Presented on the podium to the Canadian Urological Association, Quebec City, 6/97 and South Central Section of AUA, Bermuda, November, 1997
22. Slaton, J.W., Levy, D.A., El-Neggar, A. , Swanson, D. A., and Dinney, C.P.N., The predictive value of DNA ploidy in conjunction with other prognostic factors for recurrent renal cell carcinoma. Presented as a poster to the South Central Section of the AUA, Bermuda, November, 1997
23. Slaton, J.W., Perrotte, P., Bielenberg, D., Eve, B.Y., Inoue, K., Fidler, I.J., and Dinney, C.P.N., Dosing interval of alpha-interferon is critical in the downregulation of angiogenesis and invasive factors in orthotopically implanted human transitional cell carcinoma. Presented as a poster at the 88th Annual AACR Annual Meeting, New Orleans, LA, March, 1998
24. Killion, J.J., Slaton, J.W. and Nelkin, G. Generation of antitumor effector macrophages and LAKAg cells and inhibition of lung metastasis of murine renal adenocarcinoma (RENCA) with Multilamellar liposomes (MLV) which contain both lipopeptide CGP31362 and interleukin-2. Presented as a poster at the 88th Annual AACR Annual Meeting, New Orleans, LA, March, 1998.
25. Slaton, J.W., Levy, David A. , Morris, M., Swanson, D.A., Grossman, H.B., Dinney, C.P.N. Cost analysis of a stage-specific approach to tumor surveillance after radical surgery for genitourinary neoplasms. Presented on the podium at the 93rd Annual AUA at San Diego, CA, April, 1998.
26. Dinney, C.P.N., Perrotte, P., and Slaton, J.W., Impact of adjuvant chemotherapy on long-term survival of patients with lymph node metastases after radical cystectomy. Presented on the podium at the 93rd Annual AUA at San Diego, CA, April, 1998.
27. Levy D.A., Slaton, J.W., Perrotte, P., El-Naggar, A., Swanson, S.A., Dinney, C.P.N. The value of DNA ploidy in conjunction with other prognostic factors for the prediction of tumor recurrence in renal cell carcinoma (RCC). Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
28. Slaton, J.W., Nelkin, G., and Killion, J.J., Incorporation of interleukin-2 into liposomes containing macrophage activators as therapy for lung metastases of murine renal cell carcinoma (RENCA). Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.and at 2nd Annual MDACC Trainees Competition, Houston, TX, May, 1997
29. Miller, M. C., O-Dowd, G.J., Veltri, R.W., Slaton, J.W., Dinney, C.P.N., and Grossman, H.B., The effect of intravesical Bacillus Calmette-Guerin (BCG) on the predictive value of cytology and DNA ploidy. Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
30. Ellerhorst, J., Slaton, J.W., Perrotte, P., Dinney, C.P.N., and Swanson, D.A., Integration of metastasectomy into a multimodal approach for the treatment of metastatic renal cell carcinoma (RCC). Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
31. Perrotte P., Slaton, J.W. , Ellerhorst, J, and Dinney, C.P.N., The rationale for renal biopsy in symptomatic patients with advanced renal cell carcinoma being considered for nephrectomy. Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
32. Diane Bielenberg, Perrotte, P., Slaton, J. W., Eve, B.Y., Inoue, K., and Dinney, C.P.N., Systemic administration of interferon-alpha decreases expression of metallopreoteinace type 9 (MMP-9), angiogensis and growth of human transitional cell carcinoma growing in athymic nude mice. Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
32. Corral, D.A., Slaton, J.W., Perrotte, P., Dinney, C.P.N., and Grossman, H.B., The role of examination under anesthesia (EUA) in the staging and management of bladder cancer in the contemporary era. Presented on the podium at the 93rd Annual AUA at San Diego, CA, April, 1998.
33. Inoue, K., Slaton, J.W., Perrotte, P., El-Naggar, A., Pisters, L.L., and Dinney, C.P.N., The relationship of hepatocyte growth factor receptor (C-met) expression to metastasis and progression in primary and metastatic renal cell carcinoma (RCC). Presented as a poster at the 93rd Annual AUA at San Diego, CA, April, 1998.
34. Killion, J.J., Slaton, J.W., and Nelkin, G. Effector cell activation against murine renal cell adenocarcinoma and subsequent release of cytokines induced by liposome-encapsulated IL-2 and CGP31362. Presented at the Second Joint Meeting of the International Cytokine Society and International Society for Interferon and Cytokine Research. Jerusalem, Israel. Oct 26, 1998.
35. Killion, J.J., Slaton, J.W., Wilson, M.R., Pathak, S., Nelson, G. and Greenberg, N.M. Establishment and characterization of an orthotopic, therapeutic model of prostate pancer by Implantation of TRAMP C-2 cells in the prostate of syngeneic C57BL/6 mice. Presented at AACR special conference "New Research Approaches in the Prevention and Cure of Prostate Cancer" in Indian Wells, CA December 3, 1998.
36. Inoue K., Slaton, J.W., Eve, B.Y., Perrotte, P., Balbay, M.D., and Dinney, C.P.N., Interleukin-8 expression regulates tumori genicity and metastases in human bladder and prostate cancer. Presented as a poster at the 89th Annual AACR in Philadelphia, PA, April, 1999.
37. Slaton, J.W., Perrotte, P., Inoue, K., El-Naggar, A., Fidler, I.J., and Dinney, C.P.N. Relative expression of collagenase type IV and E-cadherin in radical nephrectomy specimens can predict for advanced pathologic stage. Presented as a poster at the 89th Annual AACR in Philadelphia, PA, April, 1999.
38. Inoue, K., Kim, Y-B., Slaton, J.W., Portera, C.A., Kassis, J., Ells, A., Dinney, C.P.N., and Radinsky, R. Overexpression of a motility-deficient epidermal growth factor receptor (EGF-R) in human transitional cell carcinoma (TCC) inhibits matrixmetalloprotease-9 (MMP-9)-mediated motility, angiogenesis, and metastasis in nude mice. Presented at a minisymposium at the 89th Annual AACR in Philadelphia, PA, April, 1999.
39. Karashima, T., Chiaki Yoshikawa, Shuin, T., Inoue, K., Slaton, J.W., and Dinney, C.P.N., The prognostic value of angiogenic factors for progression after cystectomy for muscle-invasive bladder cancer. Presented on the podium at the 94th Annual AUA in Dallas, TX, May, 1999.
40. Killion, J.J., Slaton, J.W., Wilson, M.R., Pathak, S., Nelkin, G., and Greenberg, N.M., Development of an immunocompetent therapeutic model of prostate cancer by implantation of TRAMP C-2 cells in the prostate of syngeneic C57BL/6 mice. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
41. Dinney, C.P.N., Slaton, J.W., Inoue, K., Perrotte, P., El-Naggar, A., Fidler, I.J., Swanson, D.A., and Dinney, C.P.N., The prognostic significance of angiogenic factor expression in renal cell carcinoma (RCC). Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
42. Pavlovich, C.P., Vaughan, E.D., Jr., Kadesky, K., Slaton, J.W., Swanson, D.A., and Dinney, C.P.N., A stage-specific surveillance protocol for patients after nephroureterectomy for upper tract transitional cell carcinoma: a multiinsitutional analysis. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
43. Radinsky, R., Inoue, K., Slaton, J.W., Kim, Y-B, Portera, C.A., Dinney, C.P.N.; Kassis, J. and Wells, A., Overexpression of a motility-deficient epidermal growth factor receptor (EGF-R) in human transitional cell carcinoma (TCC) inhibits matrixmetalloprotease-9 (MMP-9)-mediated motility, angiogenesis, and metastasis in nude mice. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
44. Morgenstern, N., Slaton, J.W., Levy, D.A., Ayala, A.,Santos, M.W. Jr., and Pettaway, C.A., Vascular invasion and tumor stage are independent prognosticators of lymph node metastasis in squamous penile cancer (SPC). Presented on the podium at the 94th Annual AUA in Dallas, TX, May, 1999.
45. Rodriguez-Villanueva, J., Slaton, J.W., Grossman, H.B. Fritsche, H.A. and Dinney, C.P.N., The effect of Bacille-Calmette Guerin (BCG) on the specificity of nuclear matrix protein 22 (NMP22) for recurrent bladder cancer. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
46. Inoue K., Slaton, J.W., Perrotte P., Eve B.Y., and Dinney C.P.N., Interleukin-8 (IL-8) expression regulates tumorigenicity and metastases in human bladder cancer. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
47. Inoue K., Eve B.Y., Slaton, J.W., Perrotte P., Balbay M.D., Pettaway C.A., and Dinney C.P.N. Interleukin-8 (IL-8) expression regulates metastases in androgen independent prostate cancer Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
48. Dinney, C.P.N., Slaton, J.W., Perrotte, P., Ellerhorst, J. and Swanson, D.A., The effect of organ site on survival after resection of a solitary renal cell carcinoma (RCC) metastasis. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
49. Pettaway, C.A., Pisters, L.L., Finn, D., Slaton, J. W., and Logothetis, C.J., Preoperative chemotherapy (CHT) and hormonal therapy (AA) followed by radical prostatectomy for locally advanced prostate cancer (PCA). Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
50. Slaton, J.W., Perrotte, P., Inoue, K., El-Naggar, A., Fidler, I.J., Swanson, D.A., and Dinney, C.P.N., Ratio of matrix metalloproteinases (MMP) to E-cadherin (Ecad) expression is an independent predictor of metastasis in renal cell carcinoma (RCC). Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
51. Balbay, M.D., Slaton, J.W., Trane, N., Skibber, J., and Dinney, C.P.N. Avoiding urinary diversion in patients with locally advanced rectal cancer: The role for bladder sparing. Presented on the podium at the 94th Annual AUA in Dallas, TX, May, 1999.
52. Perrotte, P., Wood, C.G., Inoue, K., Slaton, J.W., and Dinney, C.P.N. Basic fibroblast growth factor as a target for gene therapy in transitional cell carcinoma of the bladder bFGF gene therapy. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
53. Perrotte, P., Inoue, K., Slaton, J.W., Eve, B., and Dinney, C.P.N. Intralesional interferon gene transfer inhibits the growth of human transitional cell carcinoma (TCC) growing in athymic nude mice by inhibition of angiogenesis and activation of macrophages. Presented as a poster at the 94th Annual AUA in Dallas, TX, May, 1999.
54. Slaton, J.W., Perrotte, P., Ellerhorst, J. Dinney, C.P.N. and Swanson, D.A. Survival after resection of a solitary renal cell carcinoma (RCC) metastasis is dependent upon the site of metastasis. Presented as a poster at the First International Symposium on Renal Cancer. Chicago. IL Oct 2, 1999.
55. Slaton, J.W., Inoue, K. Perrotte, P., El-Naggar, A. K., Swanson, D.A. and Dinney, C.P.N., Metastasis-related gene expression in primary renal cell carcinoma Presented as a poster at the First International Symposium on Renal Cancer. Chicago. IL Oct 2, 1999.
56. Inoue, K., Slaton, J.W., Davis, D.W., Hicklin, D.J., McConkey, D., Karashima, T., Radinsky, R., and Dinney, C.P.N. Therapy of metastatic transitional cell carcinoma of the bladder with the anti-vascular endothelial cell growth factor receptor (flk1/KDR) monoclonal antibody DC101 and paclitaxel. Presented as a poster at Molecular Targets and Cancer Therapeutics, Washington, D.C. Nov 17, 1999 and at Cancer Research at the Millenium in Houston, TX Jan 10, 1999.
57. Inoue, K., Slaton, J.W., Perrotte, P.,Davis, D.W., Bruns, C.J., Hicklin, D.J., McConkey, D., Karashima, T., Radinsky, R., and Dinney, C.P.N. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody C225 in mice with metastatic human bladder transitional cell carcinoma. Presented as a poster at Molecular Targets and Cancer Therapeutics, Washington, D.C. Nov 17, 1999 and at Cancer Research at the Millenium in Houston, TX Jan 10, 1999.
58. Inoue, K., Slaton, J.W., Perrotte, P., Bruns, C.P., Davis, D.W., Hicklin, D.J., McConkey, D., Karashima, T. , Radinsky, R. and Dinney, C.P.N. Anti-epidermal growth factor receptor monoclonal antibody C225 enhances the effect of paclitaxel on metastatic human transitional cell carcinoma. Presented at the 91st Annual AACR in San Francisco, April 1-4, 2000.
59. Karashima, T., Inoue K., Slaton, J.W., Perrotte, P., Wood, C.G., Eve, B. and Dinney, C.P.N. Therapy with adenoviral-mediated antisense bFGF and IL-8 cDNA constructs can inhibit tumor-induced angigoenesis and tumor growth of human transitional cell carcinoma. Presented at the 91st Annual AACR in San Francisco, April 1-4, 2000.
60. Slaton, J.W., Inoue K., Slaton, J.W., Karashima, T. Moti, Pagliaro, L. Benedict, W.F. and Dinney, C.P.N. Therapy with an adenoviral p53 construct enhances cytoreductive chemotherapy of transitional cell carcinoma by augmenting apoptosis and inhibiting of angiogenesis. Presented at the 91st Annual AACR in San Francisco, April 1-4, 2000.
61. Killion, J.J., Slaton, J.W., Nelkin, G. Cytokine profile of spleen cells stimulated with liposomal-lipopeptide and IL-2 rapid release if IFN-?, continuous release of TNF-? an dproperties of cellular paralysis to release of cytokines. Presented at the 91st Annual AACR in San Francisco, April 1-4, 2000.
62. Slaton, J.W., Inoue, K. Yoshikawa, C., Shuin, T. Karashima,, T. and Dinney, C.P.N. The ratio of matrix metalloproteinase-9 to e-cadherin is an independent predictor of disease-free survival in transitional cell carcinoma of the bladder. Presented on the podium at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
63. Slaton, J.W., Perrotte, P., Balbay, M. D., Levy, D.A.Dinney, C.P.N. and Swanson, D.A. A reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
64. Izawa, J., Slaton, J.W., Czerniak, B., and Dinney, C.P.N. Differential expression of metastasis-related genes in invasive and superficial bladder tumors. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
65. Karashima,, T., Slaton, J.W., Fan, Z., Mendelsohn, J. and Dinney, C.P.N. Inhibition of angiogenesis by the anti-epidermal growth factor receptor antibody c225 in androgen independent prostate cancer growing orthotopically in nude mice. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
66. Karashima, T., Slaton, J.W., Kim, S.J., and Dinney, S.J. Low-dose interferon-? inhibits tumor-induced neovascularity and growth after chemotherapy-induced cytoreduction of transitional cell carcinoma growing in the bladder wall of athymic nude mice. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
67. Inoue, K., Slaton, J.W., Davis, D. W., Bruns, C.J., Radinsky, R., Kim S.J., Dinney, C.P.N. and Hicklin, D.J. Epidermal growth factor receptor antibody (IMC-C225) enhances paclitaxel therapy of orthotopic transitional cell carcinoma growing in nude mice. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
68. Inoue, K., Slaton, J.W., Radinsky, R., Dinney, C.P.N., and Hicklin, D.J. Vascular endothelial growth factor receptor antibody (DC101) is synergistic with paclitaxel in the treatment of human transitional cell carcinoma growing in the bladder of nude mice. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
69. Slaton, J.W., Inoue, K., Karashima, T., Tamashita, M.,, Pagliaro,, L., Benedict, W.F., and Dinney, C.P.N., Adenoviral p53 gene therapy enhances the efficacy of cytotoxic chemotherapy of transitional cell carcinoma of the bladder by increasing apoptosis and inhibiting angiogenesis. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
70. Wood, C.G., Slaton, J.W., Inoue, T. Karashima,, T., Davis, D.W., McConkey, D. and Dinney, C.P.N., Adenoviral-mediated gene therapy with antisense interleukin-8 for human prostate cancer. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
71. Slaton, J.W., Inoue, K., Tamoli, P., El-Naggar, A.K., Swanson, Dinney, C.P.N., Progression-related gene expression in resected renal cell carcinoma lung metastases. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
72. Slaton, J.W., Babaian, R.J., Bochner, B.H., Lieskovsky, G. and Skinner, D.G., Risk factor-directed surveillance for prostate specific antigen recurrence after radical prostatectomy for localized prostate cancer. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
73. Slaton, J.W., Inoue, K., Morganstern, N., Tamboli, P., Ayala, A., Dinney, C.P.N. and Pettaway, C.A., Metastasis-related gene expression predicts for positive inguinal lymph nodes in squamous penile carcinoma. Presented on the podium at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
74. Slaton, J.W., Millikan, R., Inoue, K., Czerniak, B. and Dinney, C.P.N., Metastasis-related gene expression predicts for survival in patients with locally advanced transitional cell carcinoma undergoing systemic chemotherapy and radical cystectomy. Presented on the podium at the 95th Annual AUA in Atlanta, May 2-6, 2000
75. Bevan-Thomas, R., Slaton, J.W., and Pettaway, C.A., Morbidity of inquinal lymphadenectomy for squamous penile carcinoma in the contemporary era. Presented on the podium at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
76. Inoue, K., Wood, C.G., Slaton, J.W. and Colin P.N. Dinney. Interleukin-8 is a target for gene therapy in transitional cell carcinoma of the bladder. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
77. Slaton, J.W., Okihara,, K., Troncoso, P. and Babaian R.J., A novel strategy for selecting patients for nerve-sparing radical prostatectomy. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
78. Sintuu, C., Inoue, K., Slaton, J.W., Pettaway, C.A., Dinney, C.P.N., and Wood, C.G. Angiogenesis as a target for adenoviral-mediated antisense gene therapy in urologic malignancies. Presented as a poster at the 95th Annual AUA in Atlanta, April 28-May 4, 2000.
79. Mian B., Amato R., Slaton J.W., and Pister L.P., Sarcomatoid renal cell carcinoma: The effect of multimodal therapy in the contemporary era. Presented on the podium at the South Central Section of the AUA in Montreal, Sept. 10, 2000.
80. Slaton, J.W., Inoue, K., Morganstern, N., Tamboli, P., Ayala, A., Dinney, C.P.N. and Pettaway, C.A., Metastasis-related gene expression predicts for positive inguinal lymph nodes in squamous penile carcinoma. Presented on the podium at the South Central Section of the AUA in Montreal, Sept. 9, 2000.
81. Inoue, K, Slaton J.W., Dinney, C.P.N., Karashima T., Yoshikawa C., and Shuin, T. The prognostic value of angiogenesis factor expression for predicting progression of locally advanced bladder cancer following neoadjuvant chemotherapy and readical cystectomy. Presented on the podium at the South Central Section of the AUA in Montreal, Sept. 9, 2000.
82. Bevan-Thomas, R., Slaton, J.W., and Pettaway, C.A., Contemporary morbidity of inquinal lymphadenectomy for squamous penile carcinoma. Presented on the podium at the South Central Section of the AUA in Montreal, Sept. 9, 2000.
83. Slaton J.W., Perrotte P., Babaian R.J.,Pettaway C.A., and Swanson D.A., Residual prostate tissue after radical prostatectomy: a potential cause for persistently detectable PSA levels after surgery. Presented at the Society International Urologique in Singapore, Oct 29 2000.
84. Slaton, J.W., Okihara,, K., Troncoso, P. and Babaian R.J., A novel strategy for selecting patients for nerve-sparing radical prostatectomy. Presented at the Society International Urologique in Singapore, Oct 30 2000.
85. Swanson D.A., Slaton J.W., Dinney C.P.N. Selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. Presented at the Society International Urologique in Singapore, Oct 30 2000.
86. Slaton JW, Inoue K, Perrotte P, El-Naggar A, Swanson DA, Dinney CPN High expression of progression-related genes in resected renal cell carcinoma lung metastases is associated with decreased disease-free survival. Presented at the 92nd Annual AACR in New Orleans, March 24-29, 2001
87 Kedar DM, Slaton JW, Dinney CPN, Killion JJ, Fidler IJ 0ptimal biological dose of pegilated interferon-alpha (PEG-IFN-alpha) inhibits angiogenesis and growth of human transitional cell carcinoma in the bladder of nude mice. Presented at the 92nd Annual AACR in New Orleans, March 24-29, 2001.
88. Killion JJ, Slaton JW, Nelkin G, Tumoricidal activation of macrophages and effector cells by liposome-encapsulated (MLV) CGP31362 and IL-2 results in inhibition of lung metastasis of murine renal adenocarcinoma (RENCA). Presented at the 92nd Annual AACR in New Orleans, March 24-29, 2001.
89. Huang S.F., Slaton JW, Tamboli P., Song R., Kedar D., Sweeney P., Mian B., Pettaway CA. Development and characterization of a novel orthotopic model of penile squamous carcinoma in nude mice. Presented at the 92nd Annual AACR in New Orleans, March 24-29, 2001.
90. Slaton, J.W., Wood, C.G., Kedar D., Karashima, T., and Dinney, C.P.N. Vascular endothelial growth factor is a target for gene therapy in bladder cancer. Presented as a poster at the 96th Annual AUA in Anaheim, June 1-6, 2001.
91. Slaton, J. W., Karashima, T, Perrotte P., Inoue K., Kedar D., McConkey D., Millikan, R., Yoshikawa C., Shuin T., and Dinney, C.P.N. Therapy with low-dose interferon-alpha (IFN-alpha) can restore the normal balance between MMP-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Presented as a poster at the 96th Annual AUA in Anaheim, June 1-6, 2001.
92. Slaton, J.W., Keiji I, Tamboli P., El-Naggar A.K., Swanson D.A., and Dinney, C.P.N.,
Impact of organ site on progression-related gene expression in resected renal cell carcinoma metastases. Presented as a poster at the 96th Annual AUA in Anaheim, June 1-6, 2001.
93. Kim S.J., Karashima, T, Slaton, J.W., Keiji I, and Dinney, C.P.N., Low-dose interferon-alpha inhibits tumor-induced neovascularity and growth after chemotherapy-induced cytoreduction of androgen-independent prostate cancer. Presented as a poster at the 96th Annual AUA in Anaheim, June 1-6, 2001.
94. Slaton J.W., Okihara K., Frost J., Troncoso J. and Babaian R.J. A color-labeling strategy for cost-effective site-specific identification of prostate sextant biopsy cores. Presented as poster at the 96th Annual AUA in Anaheim, June 1-6, 2001.
95. Slaton, J.W., Huang S.F., Levy D.A., and Pettaway C.A.. Lymph node-positive squamous penile carcinoma: Extent of nodal involvement predicts 3-year disease-free survival. Presented on the podium at the 96th Annual AUA in Anaheim, June 1-6, 2001.
96. Slaton, J.W., Levy D.A., Perrotte P., Dinney C.P.N., and Swanson D.A. Practical application of renal cell carcinoma prognostic factors to a risk factor driven approach to tumor surveillance after radical nephrectomy. Presented as a poster discussion at the 96th Annual AUA in Anaheim, June 1-6, 2001.
97. Mian BM, Sweeney JP, Kedar D, Slaton JW, Huang S, Czerniak B, Ward N, Dinney CP, of angiogenesis-related markers in non-transitional cell and transitional cell cancers of the bladder: explanation for aggressive biologic behavior. Presented as a poster at the 97th Annual AACR, San Francisco, CA. April 1-4, 2002, 4435A.
98. Dinney CP, Slaton JW, Shen Y,Williams S, Logothetis C, Millikan R, Prognostic significance of expression of genes related to invasion and metastasis in locally advanced bladder cancer treated with chemotherapy and surgery . Presented as a minisymposium at the 97th Annual AACR, San Francisco, CA. April 1-4, 2002, 4135A.
99. Slaton JW, Inoue K, Perrotte P, Dinney CP, Metastasis-related gene expression in renal cell carcinoma venous thrombi: a comparative analysis of patients with localized and metastatic disease. Presented as a poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
100. Slaton JW, Karashima T, Inoue K, Kim SJ, Radinsky R, Dinney CP, Fidler IJ A novel tyrosine kinase inhibitor of epidermal growth factor receptor enhances paxcitaxel therapy of orthotopic transitional cell carcinoma growing in nude mice. Presented as a poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
101. Slaton JW, Zisman A, Belldegrun A, Dinney CP, Swanson DA Validation of UCLA integrated staging system (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma Presented as a moderated poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
102. Sweeney P, Slaton JW, Munsell M, Carpenter S, Vaporciyan A, Swanson DA, Wood CG, Pisters LL, Dinney CP An analysis of prognostic factors for patients with renal cancer extending into the vena cava Presented on the podium at the 97th Annual AUA, Orlando, May 26-29, 2002.
103. Premoli JM, Anderson K, Slaton JW. Can we reduce long-term surveillance in patients with superficial transitional cell carcinoma? a feasibility study. Presented as a moderated poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
104. Slaton JW, Kedar D, Balbay MD, Dinney CP, Wood CG, Pisters LL, Swanson DA Impact of rising rates of obesity on morbidity of radical nephrectomy. Presented as a moderated poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
105. Rosser CJ, Slaton JW, Izawa J, Levy LB, Dinney CP. Clinicopathological presentation of urinary bladder sarcomas in adults. Presented on the podium at the 97th Annual AUA, Orlando, May 26-29, 2002.
106. Ercole C, Slaton JW. Decreasing rates of positive digital rectal examination during prostate cancer screening in the contemporary era. Presented as a poster at the 97th Annual AUA, Orlando, May 26-29, 2002.
107. Dinney CP, Slaton JW, Shen Y, Logothetis C, Millikan R, Williams D. Prognostic significance of expression of genes related to invasion and metastasis in locally advanced bladder cancer treated with chemotherapy and surgery J Urol 169 (4 suppl). 1424A, 2003. Presented on the podium at the 98th Annual AUA, Chicago, May 2003.
108. Slaton JW, McGee S, Anderson K, Sloper D, The antiangiogenic effects of interferon-alpha in renal cell carcinoma depends upon optimal dose and schedule J Urol 169 (4 suppl), 795A, 2003. Presented as a poster at the 98th Annual AUA, Chicago, May 2003.
109. Anderson K, Slaton JW. Should patients with other primary neoplasms be evaluated for bladder cancer? A risk-related analysis of the SEER database J Urol 169 (4 suppl). 865A, 2003. Presented as a poster at the 98th Annual AUA, Chicago, May 2003.
110. Anderson JK, Sloper S, Slaton JW, Chemo-induction of pro-angiogenic genes in transitional cell carcinoma of the bladder J Urol 169 (4 suppl). 529A, 2003. Presented as a poster at the 98th Annual AUA, Chicago, May 2003.
111. Sloper D, McGee S, Anderson JK; El-Naggar A, Swanson DA, Dinney C, Slaton JW, A comparison of organ-specific progression-related gene expression between resected human renal cell carcinoma (RCC) metastases and spontaneous metastases derived from an orthotopic murine model of RCC. J Urol 169(4 suppl), 547A, 2003. Presented as a poster at the 98th Annual AUA, Chicago, May 2003.
112. Schwartz S, Wasserman NF, Slaton JW. The impact of extended biopsy strategies on the need for repeat biopsies in patients with prostate intraepithelial neoplasia. J Urol 169 (4, suppl). R6431A, 2003. Presented as a poster at the 98th Annual AUA, Chicago, May 2003.
113. Unger G, Slaton J, Adams G, Davis Alan, Ahmed K. Antisense formulation via sub 50nm nanoencapsulation enhances effectiveness of problematic medicinal chemistry for tumor specific antisense to CK2. Proc Ann Meeting AACR, 45:R6431A, 2003. Presented as a poster at the 94th Annual AACR, Washington DC, May 2003.
114. Slaton JW, Sloper DT, Taylor M, Davis A, Ahmed K Antisense CK2 gene therapy induces apotosis in prostate cancer ut not normal prostate epithelium. J Urol 171 (5 suppl), 1111A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
115. Slaton JW, Taylor M, Sloper DT, Towers N, McKenna D, Wilson MJ. Mushroom extracts inhibit growth and metastasis of renal cell carcinoma. J Urol 171 (5 suppl), 993A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
116. Slaton JW, Sloper, DT, Anderson JK. The response of renal cell carcinoma to the antiangiogenic effects of interferon-alpha varies in an organ-specific manner. J Urol 171 (5 suppl), 992A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
117. Slaton JW, Sloper DT, Taylor M, Davis A, Ahmed K. Antisense CK2 gene therapy induces regression in human bladder cancer growing in athymic nude mice. J Urol 171 (5 suppl), 972A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
118. Slaton JW, Nakib N, Wasserman N, Schwartz S. The presence of concurrent atypia in patients with prostatic intraepithelial neoplasia found on extended core biopsy predicts for cancer on repeat biopsy. J Urol 171 (5 suppl), 642A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
119. Juan Premoli, Anderson K and Slaton JW. Risk factors for upper urinary tract recurrences in patients undergoing long-term surveillance for superficial bladder cancer. J Urol 171 (5 suppl), 295A, 2004. Presented as a poster at the 99th Annual AUA, San Francisco, May 2004.
120. Slaton JW, Sloper DT, Anderson JK. Organ-specific expression of progression-related genes and organ-specific response to low-dose interferon-alpha in a murine model of human renal cell carcinoma. Proc Ann Meeting AACR 45:4112A, 2004. Presented as a poster at the 94th Annual AACR, Washington DC, May 2003.
Top of page
INVITED PRESENTATIONS:
Macrophage activators in combination with IL-2 as therapy for murine models of renal and prostate cancer. Oncology Seminar. Fox-Chase Cancer Center, Philadelphia, Nov 13, 1997.
A surgical approach to advanced renal carcinoma. H. Lee Moffit Cancer Center, Tampa, FL, May 25th, 1998.
Prognostic factors for renal cell carcinoma. Urology Grand Rounds, University of Chicago School of Medicine, Chicago, IL, September 23, 1998.
The rationale for renal biopsy as an aid in the selection of patients with metastatic renal cell carcinoma (RCC) for cytoreductive nephrectomy. First International Symposium on Renal Cancer, Chicago, IL, Oct 1, 1999.
Optimal dosing of interferon-alpha for the inhibition of angiogenesis in bladder cancer, University of Southern California, Department of Urology, 3/15/00.
Organ-specific expression of metastatic renal cancer. National Kidney Cancer Association, San Francisco, CA, 7/30/01.
New horizons in therapy for bladder cancer – Presented at the Bladder Cancer Symposium, 3M Corporation, St Paul, MN, 7/1501.
Effect of IL-8 on Matrix metalloprotease, Prostate Cancer Research Forum, University of Minnesota, 9/18/01
Low-dose interferon-alpha as a therapeutic strategy for metastatic renal cancer, The Minneapolis Kidney Cancer Association, 10/9/01.
Shared Decision-making for PSA Surveillance, Geriatric Medicine and Pharmacology, Minneapolis, 3/21/02
Top of page
Return to: Medical School : Academic Health Center : myU : U of M Home
